DexCom (DXCM) is back in focus after its latest quarterly update, which combined higher second quarter revenue and net income with a raised full year sales outlook and confirmation of a completed share repurchase program.

The latest earnings release and higher full year revenue guidance have coincided with a strong upswing in DexCom's share price, including a 57.04% 90 day share price return and 36.46% year to date share price return, while the 3 year total shareholder return declined 18.32%.

If DexCom's recent momentum has you looking across diabetes and metabolic health technology, it can be useful to see how peers are trading in adjacent areas using the 43 healthcare AI stocks.

After a 57% move in 90 days and fresh guidance from DexCom, the real fork in the road is whether you accept today’s price as fair for its progress, or hold out for a cheaper entry as the valuation case unfolds.

Most Popular Narrative: 90% Undervalued

DexCom's most followed valuation narrative pegs fair value at $91.64, which sits close to the recent $90.80 close, yet its own fair value framework still points to a steep discount.

The recent expansion of insurance reimbursement for type 2 non-insulin diabetes patients now covering nearly 6 million lives across the three largest U.S. PBMs opens a large, previously untapped segment of DexCom's addressable market, driving new patient growth and supporting robust multi-year revenue expansion.

Curious what has to happen for that fair value to hold up. The narrative leans on faster earnings, firm margins, and a richer future multiple. The exact mix of growth, profitability and discount rate assumptions is where the story really gets interesting.

Result: Fair Value of $91.64 (UNDERVALUED)

However, DexCom's story could look very different if Medicare pricing pressure or faster moving competitors squeeze margins and slow the uptake that underpins this narrative.

Another View: What DexCom’s P/E Is Telling You

While the dominant DexCom narrative leans on a fair value of $91.64, the current P/E of 34.3x paints a different picture. It sits above the US Medical Equipment industry at 26.3x, the peer average at 26.5x, and the 32.5x fair ratio that the market could move toward. That gap points to valuation risk if expectations cool from here.

For investors weighing up DexCom after the recent share price move, the question is simple: Does the earnings quality and growth outlook justify paying more than both peers and the fair ratio, or is this where discipline on entry price starts to matter most?

Next Steps

If this DexCom discussion seems divided between opportunity and valuation risk, it may help to move quickly from headline narratives to hard data and your own verdict. To see what the market is already optimistic about, review the 3 key rewards

Looking for more DexCom investment ideas?

If DexCom has sharpened your focus on where to put fresh capital, do not stop here. The opportunities you miss now could matter most later.

• Hunt for quality at a discount and see which companies stand out in the 49 high quality undervalued stocks.
• Build a steadier income stream by focusing on companies featured in the 9 dividend fortresses.
• Prioritise resilience and capital protection with stocks highlighted through the 85 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.